

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/tcr-22-2547	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	All the data used in this study can be shared if necessary (There's no patient privacy part involved).
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Study protocol, statistical analysis plan, etc. will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the technique or survival data may be updated over time.
7	To whom will you share the data?	Medical oncologists and breast surgeons who are interested in our study.
8	For what type of analysis or purpose?	For analysis to evaluate the efficacy, cardiotoxicity and factors affecting pathologic complete response of neoadjuvant chemotherapy with anthracycline-containing verses anthracycline-free regimens plus dual HER2 blockade for HER2-positive early-stage breast cancer.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: sun137@sina.com

10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.
----	-------------------------	--